Kura Oncology (NASDAQ: KURA) CCO sells stock to cover RSU taxes

Rhea-AI Filing Summary

Kura Oncology’s Chief Commercial Officer Brian T. Powl reported routine share sales related to tax withholding on vested restricted stock units. On January 27, 2026, he sold 4,842 and 1,572 shares of common stock at prices of $8.4606 and $8.4607 per share, respectively, as sell-to-cover transactions for RSUs granted on January 2, 2025 and January 2, 2024. Following these sales, he directly owned 183,275 shares of Kura Oncology common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Powl Brian T.

(Last) (First) (Middle)

C/O KURA ONCOLOGY, INC.

4930 DIRECTORS PLACE, SUITE 500

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kura Oncology, Inc. [ KURA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/27/2026		S		4,842	D(1)	$8.4606	184,847	D
Common Stock	01/27/2026		S		1,572	D(2)	$8.4607	183,275	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Sell-to-cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 1/2/25.

2. Sell-to-cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 1/2/24.

	Teresa Bair, Attorney-in-fact for Brian Powl	01/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Kura Oncology (KURA) report for Brian T. Powl?

Brian T. Powl reported small stock sales to cover taxes on vested RSUs. On January 27, 2026, he sold 4,842 and 1,572 Kura Oncology common shares as routine sell-to-cover transactions related to previously granted restricted stock units.

How many Kura Oncology (KURA) shares did Brian T. Powl sell and at what prices?

He sold 4,842 shares at $8.4606 and 1,572 shares at $8.4607 per share. Both transactions occurred on January 27, 2026 and involved Kura Oncology common stock in tax-related sell-to-cover trades.

Why did Kura Oncology’s Chief Commercial Officer sell KURA shares?

The sales were sell-to-cover transactions for taxes on vested RSUs. Footnotes state the trades covered tax obligations from restricted stock units granted on January 2, 2025 and January 2, 2024, rather than discretionary open-market selling.

How many Kura Oncology (KURA) shares does Brian T. Powl own after the transactions?

After the reported trades, Brian T. Powl directly owned 183,275 Kura Oncology common shares. This figure reflects his beneficial ownership following the January 27, 2026 sell-to-cover transactions associated with vested restricted stock units.

What is Brian T. Powl’s role at Kura Oncology (KURA) in this Form 4 filing?

Brian T. Powl is identified as Kura Oncology’s Chief Commercial Officer. The Form 4 records his personal holdings and tax-related sell-to-cover stock sales as an executive officer under Section 16 reporting requirements.

Were any derivative securities reported in this Kura Oncology (KURA) Form 4?

No derivative transactions were listed in Table II for this filing. The only reported activity involved non-derivative Kura Oncology common stock, linked to the vesting of restricted stock units and related tax sell-to-cover sales.